Sanofi Launches Retail-Exclusive Large-Pack Oral Antidiabetic Medication to Enhance Patient Adherence

　　【Pharmaceutical Network | Industry Trends] Diabetes is a common chronic disease. Long-term hyperglycemia may cause chronic damage and functional impairment to organs and tissues such as the eyes, heart, blood vessels, and nerves. With the intensifying aging population and increasing work pressure in China, the prevalence of diabetes is also on the rise. Newly released epidemiological data show that the prevalence of diabetes among adults aged 18 and above in mainland China has reached as high as 12.8%. Based on this estimate, the number of adult diabetes patients in China has reached 129.8 million.
 

It is understood that chronic disease management “depends on daily diligence.” For patients with diabetes, taking medication regularly and at the prescribed dosage and timing—provided that the medications used can effectively control blood glucose—is essential to improving medication adherence. As most diabetic patients are middle-aged or elderly, many struggle with irregular medication intake due to inconvenience in purchasing medications or poor memory. To help patients better manage their diabetes, Sanofi recently partnered with chain pharmacies to launch a “retail-exclusive” large-pack version of Amaryl (glimepiride tablets), a commonly used oral hypoglycemic agent, upgrading the package size from the original 15 tablets to 60 tablets.
 

This also means that, in the future, diabetic patients in regions such as Jiangsu, Zhejiang, Hebei, Guangdong, and Liaoning will be able to purchase medications directly from pharmacies with a valid prescription, obtaining a one- to two-month supply at a time.
 

Data indicate that glimepiride tablets are a third-generation sulfonylurea oral hypoglycemic agent, acting as a sulfonylurea insulin secretagogue. It is an orally administered intermediate- to long-acting sulfonylurea antidiabetic medication and is included in the National Reimbursement Drug List. Furthermore, glimepiride tablets require only once-daily dosing, are unaffected by meal intake, offer high convenience, and help improve patient medication adherence.
 

Behind the launch of the “retail-exclusive” large-packaging formulation of glimepiride tablets, it is evident that the functions of chain pharmacies are being upgraded, playing an increasingly important role in promoting chronic disease management. Currently, the country is vigorously advancing a care philosophy shift from “disease-centered” to “health-centered.” In this context, as an effective complement to hospital services, chain pharmacies will become a key player in driving the realization of a closed-loop system for chronic disease management services.
 

From an industry perspective, diabetes treatment is a long-term, comprehensive management process that requires continuous adjustments as the disease progresses. Given the current limitations in medical resources, chain pharmacies and other entities need to play a greater role by assuming more responsibilities in chronic disease management. By forming complementary advantages with hospitals and communities, they can help patients with diabetes win the "protracted war" of blood glucose control.
 

In addition to retail services, chain pharmacies also provide health consultations, medication guidance, disease education, and blood glucose and blood pressure monitoring, serving as “health stewards” for patients with diabetes. Recently, pharmacies have introduced “pharmacy-exclusive” large-pack formats, which not only help patients secure a longer supply of medications but also further improve medication adherence, effectively “reducing the burden” of daily disease management.
 

Sanofi, the French pharmaceutical giant leading this initiative, has launched cost-effective, large-pack “pharmacy-customized” versions of its products. Industry observers view this move as an effort to align with the national promotion this year of “long-prescription” services, which allow patients with chronic diseases to receive prescriptions covering more than two weeks’ worth of medication at a time.
 

In addition to glimepiride tablets, Sanofi has also launched “pharmacy-customized” bulk packages of two cardiovascular and cerebrovascular drugs, Aprovel and Plavix. The packaging has been “upgraded” from the original 7-tablet pack to a 28-tablet pack, while still remaining eligible for medical insurance reimbursement. With a valid prescription, patients can purchase approximately one month’s supply at designated medical insurance pharmacies in a single visit, thereby reducing the frequency of pharmacy trips and significantly improving medication adherence.